肿瘤细胞治疗研究
英文原题：No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.
尽管近期取得了进展，多发性骨髓瘤对大多数患者仍基本上无法治愈，尤其是具有高危细胞遗传学特征的患者以及在接受 BCMA 靶向治疗后疾病复发的患者。
尽管近期取得了进展，多发性骨髓瘤对大多数患者而言本质上仍无法治愈，尤其是那些具有高危细胞遗传学特征以及在接受 BCMA 靶向治疗后疾病复发的患者。一种靶向 CD70 的新型 CD27 CAR_sIL15 NK 细胞可能为这一亟待满足的医疗需求领域带来新希望。参见 Lin 等人的相关文章，第 234 页。
Despite recent advances, multiple myeloma remains essentially incurable for most patients, particularly those with high-risk cytogenetics and those whose disease relapses after BCMA-targeting therapies. A novel CD27 CAR_sIL15 NK cell targeting CD70 may offer new hope in this area of urgent, unmet medical need. See related article by Lin et al., p. 234.
MEMBER ACCOUNT
登录成功会直接打开下一页。
